BlackRock’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-5,507,032
Closed -$731M – 5807
2026
Q2
$731M Buy
5,507,032
+1,421,381
+35% +$128M 0.01% 936
2026
Q1
$344M Buy
4,085,651
+301,657
+8% +$21.9M 0.01% 1348
2025
Q4
$286M Buy
3,783,994
+1,097,968
+41% +$69.2M ﹤0.01% 1463
2025
Q3
$107M Buy
2,686,026
+123,487
+5% +$4.72M ﹤0.01% 2064
2025
Q2
$111M Sell
2,562,539
-348,290
-12% -$13.2M ﹤0.01% 1971
2025
Q1
$109M Sell
2,910,829
-134,129
-4% -$5.19M ﹤0.01% 1929
2024
Q4
$138M Buy
3,044,958
+69,041
+2% +$3.52M ﹤0.01% 1889
2024
Q3
$175M Buy
2,975,917
+233,368
+9% +$11.2M ﹤0.01% 1740
2024
Q2
$108M Sell
2,742,549
-67,276
-2% -$3.27M ﹤0.01% 1974
2024
Q1
$187M Buy
2,809,825
+1,165,788
+71% +$50.9M ﹤0.01% 1689
2023
Q4
$45.9M Sell
1,644,037
-17,360
-1% -$348K ﹤0.01% 2526
2023
Q3
$35.4M Buy
+1,661,397
New +$36.6M ﹤0.01% 2616

Other funds holding APGE

BlackRock's APGE Position: Q3 2026 in Review

BlackRock sold out of Apogee Therapeutics (APGE) in Q3 2026, closing a stake of 5,507,032 shares — an estimated $731M sold.

BlackRock first reported a position in APGE in Q3 2023 and held it in 12 quarters. The position peaked at $731M in Q2 2026. 3 funds tracked by Wall St. Rank hold APGE as of Q3 2026.

  • BlackRock reported no remaining Apogee Therapeutics position as of Q3 2026 after selling out during the quarter.
  • BlackRock sold 5,507,032 Apogee Therapeutics shares in Q3 2026, an estimated $731M.
  • BlackRock first reported a position in Apogee Therapeutics in Q3 2023 and held it in 12 quarters.
  • BlackRock's Apogee Therapeutics position peaked at $731M in Q2 2026.
  • 3 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.